Derivatives of pyridilethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, process for their preparation and pharmaceutical compositions containing them
申请人:Lek Pharmaceuticals d.d.
公开号:US07560474B2
公开(公告)日:2009-07-14
The novel derivatives of pyridilethanol (phenylethyl) amines of formula I
are described wherein n is an integer from 1 to 4, R1 is a hydrogen atom, hydroxyl group or lower C1-6alkoxy group R2 is a hydrogen atom or a straight or branched lower C1-6alkyl group X, is hydrogen, fluorine, chlorine, bromine, hydroxyl group, trifluoromethyl group, 3,4-di-Cl,2,4-di-Cl or lower C1-6alkoxy group, the enantiomers, diastereoisomers or racemates thereof or the physiologically acceptable acid addition salts thereof which are ligands of sigma receptors for inhibiting cholesterol biosynthesis and are thus appropriate for the treatment of hypercholesterolemia and hyperlipemia in humans. The greatest lowering of cholesterol was observed by 1-(d-pyridyl)-2-(N-(2-(3,4-dicholorophenyl)ethyl-N-propylamino)ethanol in the form of dihydrobromide salt (signature BK-35, 2HBr).
本文描述了公式I的吡啶乙醇(苯乙基)胺的新衍生物,其中n为1至4的整数,R1为氢原子、羟基或较低的C1-6烷氧基,R2为氢原子或直链或支链的较低的C1-6烷基基团,X为氢、氟、氯、溴、羟基、三氟甲基基团、3,4-二氯、2,4-二氯或较低的C1-6烷氧基,其对sigma受体的配体,可抑制胆固醇生物合成,因此适用于治疗人类高胆固醇血症和高脂血症。1-(d-吡啶基)-2-(N-(2-(3,4-二氯苯基)乙基-N-丙基氨基)乙醇)的胆溴盐形式(签名BK-35,2HBr)可观察到最大的降低胆固醇作用。